MedPath

Ixinity Demonstrates Strong Safety and Efficacy Profile in Young Hemophilia B Patients

• Phase 3/4 trial shows Ixinity (trenonacog alfa) effectively prevents and controls bleeding in children under 12 with severe or moderately severe hemophilia B, leading to FDA approval expansion.

• Clinical results reveal a median annual bleeding rate of 0.86, with 33.3% of participants remaining completely bleed-free throughout the study period.

• The treatment demonstrated excellent safety with only one non-serious allergic reaction reported, while maintaining efficacy comparable to results seen in adults and adolescents.

A Phase 3/4 clinical trial has validated the safety and efficacy of Ixinity (trenonacog alfa) in young children with hemophilia B, marking a significant advancement in treatment options for pediatric patients with this rare bleeding disorder.
The study, which supported the FDA's recent approval expansion, evaluated 21 children under 12 years old with severe or moderately severe hemophilia B. Thirteen participants had severe disease with factor IX activity below 1% of normal levels, while eight had moderately severe disease with activity between 1% and 2% of normal levels.

Clinical Efficacy and Bleeding Control

The trial demonstrated remarkable efficacy in bleeding prevention, with participants achieving a median annual bleeding rate of just 0.86. Notably, one-third of the study participants remained completely free from bleeding episodes throughout the trial period, and 61.9% experienced no spontaneous bleeds.
When bleeding episodes did occur, they were effectively managed with Ixinity. Of the 52 total bleeds reported, approximately 20% required no intervention, while the remainder were successfully controlled with just one or two infusions. Participants consistently rated the treatment's efficacy as good or excellent for bleeding control.

Pharmacological Profile and Dosing

Initial pharmacological assessment involved a single infusion of 75 IU/kg, revealing that Ixinity reached peak blood concentrations within 30 minutes. The therapy demonstrated a mean half-life of 16.3 hours, supporting its approved twice-weekly dosing schedule.
During the prophylactic phase, patients received treatment within the recommended dose range of 35-75 IU/kg twice weekly. The majority of participants completed at least 50 days of exposure, equivalent to approximately six months of treatment.

Safety and Tolerability

The safety profile proved highly favorable, with only one non-serious allergic reaction reported as treatment-related, leading to early withdrawal. While some patients developed antibodies targeting factor IX, these did not impact treatment effectiveness. The results showed no clinically significant differences between children under 6 and older participants.

Treatment Implications

"This study showed that [Ixinity] was safe and effective as prophylaxis and for controlling bleeds in previously treated persons with hemophilia [younger than] 12 years," the researchers noted. The findings demonstrate comparable efficacy and safety profiles to those previously observed in adults and adolescents, establishing Ixinity as a viable treatment option for pediatric hemophilia B patients.
The successful trial results have significant implications for pediatric hemophilia B management, offering younger patients access to an effective prophylactic and on-demand treatment option. This expansion of therapeutic choices represents an important step forward in addressing the needs of children with this challenging bleeding disorder.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Novo Nordisk's Mim8 Shows Promise in Phase III Pediatric Hemophilia A Trial

Novo Nordisk's bispecific antibody Mim8 demonstrated strong safety and efficacy in Phase III FRONTIER3 trial, with 74.3% of children experiencing no treated bleeds over 26 weeks.
The trial enrolled 70 children aged 1-11 with hemophilia A, showing particular success in patients with inhibitors, as none required coagulation factor treatment for bleeding events.

Hemgenix Gene Therapy Shows Sustained Efficacy in Hemophilia B Patients After Four Years

Data from the HOPE-B trial demonstrates that Hemgenix (etranacogene dezaparvovec-drlb) provides long-term bleed protection for adults with hemophilia B.
Patients treated with Hemgenix experienced a 90% reduction in adjusted annualized bleeding rate (ABR) at year four compared to the lead-in period.

Pfizer's Gene Therapy Fidanacogene Elaparvovec Shows Promise in Haemophilia B Treatment

Pfizer's fidanacogene elaparvovec (SPK-9001) gene therapy met its primary endpoint in the Phase 3 BENEGENE-2 study for haemophilia B, demonstrating non-inferiority and superiority in annualized bleeding rate.
The BENEGENE-2 study showed a 71% reduction in annualized bleeding rate (ABR) with fidanacogene elaparvovec compared to the pre-treatment period in adult males with moderately severe to severe haemophilia B.

FDA Approves Hympavzi (marstacimab-hncq) as Novel Treatment for Hemophilia A and B

The FDA has approved Hympavzi (marstacimab-hncq), a novel monoclonal antibody, for hemophilia A and B in patients 12 years and older.
Hympavzi offers a new mechanism by reducing tissue factor pathway inhibitor, enhancing thrombin production to facilitate blood clotting.

Fidanacogene Elaparvovec Demonstrates Strong Efficacy in Hemophilia B Gene Therapy Trial

Fidanacogene elaparvovec gene therapy significantly reduces bleeding episodes in hemophilia B patients compared to baseline.
The Phase 3 open-label study showed a substantial decrease in annualized bleeding rates post-therapy with stable factor IX activity.

FDA Approves Hympavzi (marstacimab-hncq) for Hemophilia A and B Treatment

The FDA has approved Hympavzi (marstacimab-hncq) for routine prophylaxis to reduce bleeding episodes in hemophilia A without factor VIII inhibitors and hemophilia B without factor IX inhibitors.
Hympavzi is a novel treatment that targets tissue factor pathway inhibitor, an anticoagulation protein, to enhance thrombin generation and improve blood clotting.

Beqvez Gene Therapy Shows Sustained Reduction in Bleeding for Hemophilia B Patients

A single infusion of Beqvez (fidanacogene elaparvovec) gene therapy resulted in a 71% reduction in bleeding episodes in hemophilia B patients.
Over half of the patients in the study experienced no bleeding episodes following the gene therapy treatment.

FDA Approves Armour's Mononine, the First Monoclonal Antibody-Purified Hemophilia B Therapy

The FDA approved Armour's Mononine on August 20 for preventing and controlling bleeding in Hemophilia B patients with Factor IX deficiency.
Mononine, a Coagulation Factor IX, is the first monoclonal antibody-purified Hemophilia B therapy, priced at $1.04 per unit.

Gene Therapy for Hemophilia A Shows Sustained Clotting Factor Expression and Reduced Bleeding

A novel gene therapy, SPK-8011, demonstrates stable coagulation factor VIII expression in hemophilia A patients, offering a potential long-term treatment option.
The phase 1/2 trial showed a 91.5% reduction in bleeding episodes among participants, with most maintaining FVIII expression for the duration of the study.

Catalyst Biosciences Announces Positive Factor IX Clinical Data

Catalyst Biosciences, Inc. has announced positive clinical data from the first Cohort of its ongoing Phase 1/2 proof-of-concept clinical trial for CB 2679d, a next-generation coagulation Factor IX variant, in individuals with severe hemophilia B. The data shows CB 2679d is approximately 22 times more potent than current hemophilia B therapy, with a longer circulation time in the body.

Reference News

[1]
Ixinity safe, effective in young children with hemophilia B: Trial
hemophilianewstoday.com · Feb 21, 2025
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy